[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Catherine A. Sohn, a director of Maze Therapeutics, Inc. (MAZE), was granted a stock option on 09/22/2025 to purchase 18,000 shares of common stock at an exercise price of $23.67 per share. The option award vests monthly as to 1/9 of the total award, with the first tranche vesting on October 1, 2025, subject to continued service. The reported derivative shows 18,000 underlying shares and the reporting person is listed as owning 18,000 shares directly following the transaction. The form was signed by an attorney-in-fact on 09/24/2025.

Positive

• 18,000 stock options granted to a company director, clearly disclosed in the Form 4
• Exercise price specified at $23.67 per share, providing a clear basis for valuation or comparison
• Vesting schedule disclosed: 1/9 monthly with the first tranche vesting on October 1, 2025

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director received an 18,000-share option grant with staged monthly vesting beginning Oct 1, 2025.

The Form 4 documents a standard equity grant to a board member, specifying an exercise price of $23.67 and monthly vesting of 1/9 of the award with the first vesting tranche on October 1, 2025. The signature by an attorney-in-fact on 09/24/2025 is procedural. This disclosure is routine for director compensation and contains the essential dates, size, and strike price investors need to track potential dilution when options vest and are exercised.

Compensation Analyst

TL;DR: 18,000 options granted exercisable at $23.67; vesting schedule and expiration are provided in the filing.

The filing lists a derivative award of 18,000 stock options with an exercise price of $23.67 and an apparent expiration date reflected in the table. The explicit vesting schedule—1/9 monthly with first vesting on October 1, 2025—indicates a multi-year service-based equity award. The disclosure allows calculation of potential future dilution and timing of when shares may enter circulation but does not include fair-value or accounting expense details.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sohn Catherine A.

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.67	09/22/2025		A		18,000		(1)	09/21/2035	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Catherine A. Sohn report on the Form 4 for MAZE?

She reported a grant of 18,000 stock options on 09/22/2025 with an exercise price of $23.67 and monthly vesting of 1/9 starting October 1, 2025.

How many shares does the option cover and what is the exercise price?

The option covers 18,000 underlying common shares with an exercise price of $23.67 per share.

When does the option vest according to the filing?

The option vests monthly as to 1/9 of the award, with the first tranche vesting on October 1, 2025, subject to continued service.

What ownership is reported following the transaction?

The filing shows 18,000 shares beneficially owned following the reported transaction, held directly.

Who signed the Form 4 and when was it filed?

The form was signed by Courtney Phillips as attorney-in-fact and dated 09/24/2025; the transaction date is 09/22/2025.